# Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

> **NCT07228403** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Zealand Pharma** · enrollment: 35 (estimated)

## Conditions studied

- Short Bowel Syndrome (SBS)

## Interventions

- **DRUG:** Glepaglutide 10 mg

## Key facts

- **NCT ID:** NCT07228403
- **Lead sponsor:** Zealand Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-12-11
- **Primary completion:** 2028-09-18
- **Final completion:** 2028-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07228403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07228403, "Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07228403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*